Get the Stockscreener App
338.17
0.33%
-1.40
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $338.17, with a volume of 1.69M.
It is down -0.33% in the last 24 hours and down -2.96% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$339.57
Open:
$335.01
24h Volume:
1.69M
Relative Volume:
0.63
Market Cap:
$182.39B
Revenue:
$36.74B
Net Income/Loss:
$7.71B
P/E Ratio:
23.76
EPS:
14.2333
Net Cash Flow:
$8.10B
1W Performance:
-2.16%
1M Performance:
-2.96%
6M Performance:
+16.00%
1Y Performance:
+17.29%
1-Day Range:
$333.55
$338.94
1-Week Range:
$333.55
$350.69
52-Week Range:
$261.43
$391.29
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, AZN, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
338.34 | 183.05B | 36.74B | 7.71B | 8.10B | 14.23 |
LLY
Lilly Eli Co
|
855.72 | 780.79B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
226.91 | 548.34B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
204.89 | 349.67B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
184.58 | 289.51B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
110.95 | 271.76B | 64.93B | 18.26B | 12.36B | 7.2751 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Hold |
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Amgen Inc. $AMGN Shares Purchased by Vest Financial LLC - MarketBeat
Earnings To Watch: Amgen (AMGN) Reports Q1 Results Tomorrow - Yahoo Finance
Amgen Inc. $AMGN Shares Purchased by Keybank National Association OH - MarketBeat
How Will Amgen Stock React To Its Upcoming Earnings? - Trefis
US FDA Details Data Manipulation, False Statements In Tavneos Withdrawal Request - Citeline News & Insights
Amgen (AMGN) and AstraZeneca (AZN) Launch Real-Time Clinical Tri - GuruFocus
Paradigm Health collaborates with FDA to transform regulatory review of clinical trial data - marketscreener.com
Amgen, Astra launch real-time trials as FDA to expedite drug development using AI - Seeking Alpha
Feds allege that Bay Area company manipulated results of study that led to multibillion-dollar buyout - The Business Journals
FDA Review Panel Challenges Amgen's Tavneos Approval On Efficacy, Data Grounds - Benzinga
FDA Announces Major Steps to Implement Real-Time Clinical Trials - GlobeNewswire Inc.
AstraZeneca, Amgen partner with FDA to test real-time AI trial monitoring - Investing.com
Is It Too Late To Consider Amgen (AMGN) After Strong One Year Share Price Gains? - simplywall.st
Amgen to Report Q1 Earnings: Can It Keep the Beat Streak Alive? - Yahoo Finance
Did Amgen's Subsidiary Manipulate Data To Secure Tavneos Approval? - RTTNews
Amgen (NASDAQ:AMGN) Stock Price Expected to Rise, Morgan Stanley Analyst Says - MarketBeat
Amgen's Tavneos Faces FDA Withdrawal Proposal Amid Safety Concer - GuruFocus
Amgen faces U.S. withdrawal of rare disorder therapy Tavneos - Seeking Alpha
Wealthfront Advisers LLC Has $26.93 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
AMGN Faces Withdrawal Proposal for Tavneos Amid Effectiveness Co - GuruFocus
Amgen Inc. $AMGN Shares Purchased by Mitsubishi UFJ Trust & Banking Corp - MarketBeat
FDA claims Amgen drug data were ‘manipulated’; Erasca slides despite ‘home run’ results - Yahoo Finance
FDA proposes to withdraw Amgen’s rare autoimmune disease drug - whbl.com
FDA proposes to withdraw Amgen's drug for rare autoimmune diseases over effectiveness - Reuters
FDA says CDER proposed to withdraw approval of Tavneos - marketscreener.com
Amgen Inc. stock underperforms Monday when compared to competitors - MarketWatch
Pharma bets a little-known form of cholesterol will underpin its next blockbuster heart drugs - CNBC
Amgen Partners with STEM Goes Red to Inspire Women in Science and Technology - WTTE
Exploring Analyst Estimates for Amgen (AMGN) Q1 Earnings, Beyond Revenue and EPS - Yahoo Finance
Amgen Inc. $AMGN Shares Purchased by Pictet Asset Management Holding SA - MarketBeat
Kestra Private Wealth Services LLC Purchases 4,090 Shares of Amgen Inc. $AMGN - MarketBeat
State of Michigan Retirement System Sells 4,600 Shares of Amgen Inc. $AMGN - MarketBeat
Comerica Bank Has $50.76 Million Stake in Amgen Inc. $AMGN - MarketBeat
D.A. Davidson & CO. Has $81.22 Million Holdings in Amgen Inc. $AMGN - MarketBeat
Why Amgen Inc. (AMGN) is One of the Best Stem Cell Therapy Stocks to Buy - Insider Monkey
MSN Money - MSN
Amgen Inc. stock (US0311621009): Is its obesity drug pipeline strong enough to unlock new upside? - AD HOC NEWS
Vanguard Group Inc. Raises Stock Position in Amgen Inc. $AMGN - MarketBeat
Munich Reinsurance Co Stock Corp in Munich Has $1.14 Million Holdings in Amgen Inc. $AMGN - MarketBeat
A Look At Amgen (AMGN) Valuation As New AI Focused Leadership Team Takes Shape - simplywall.st
Amgen Inc. (NASDAQ:AMGN) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Amgen’s AI-Focused Leadership Reshuffle Could Be A Game Changer For Amgen (AMGN) - Yahoo Finance
Amgen Tracks Long-Term Romosozumab Safety in Children: What Investors Should Know - TipRanks
Amgen Stock (AMGN) Opinions on Q1 Earnings Preview - Quiver Quantitative
Amgen Inc. $AMGN Shares Sold by Mattern Capital Management LLC - MarketBeat
Amgen Inc. (AMGN) Announces Executive Leadership Transition - GuruFocus
5 Best Stem Cell Therapy Stocks to Buy - Insider Monkey
Wall Street Zen Downgrades Amgen (NASDAQ:AMGN) to Hold - MarketBeat
Amgen (AMGN) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance
Robert Bradway: Biotech Veteran, Strategic Dealmaker, and Amgen Chairman and CEO - BBN Times
Q1 2026 results announcement pushes Amgen stock down 1.17% - Traders Union
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Amgen Inc Stock (AMGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Santos Esteban | EVP, Operations |
Feb 26 '26 |
Option Exercise |
169.19 |
54,792 |
9,270,143 |
107,119 |
| Santos Esteban | EVP, Operations |
Feb 26 '26 |
Sale |
379.12 |
54,792 |
20,772,595 |
76,618 |
2.25%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):